Global Blood Therapeutics, Inc. (GBT) insider have most recently took part in a trading activity. On Dec 19, 2017 Perceptive Life Sciences Master Fund Ltd, 10% Owner bought 175,000 shares having total worth of $6,650,000 at the price of $38 per share, following the transaction a total of 4,889,066 shares owned by Perceptive Life Sciences Master Fund Ltd.
The stock has experienced a total of 4 insider trades in the past three months. These trades include 4 sell activities .Furthermore, over the past 12 months , the stock was traded 11 times by insiders. In 11 of these trades, the insider was a seller .
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Global Blood Therapeutics, Inc. (GBT) traded up 1.52% on Dec 18, 2017, hitting $36.8. 1,164,380 shares of the company’s stock traded hands. Global Blood Therapeutics, Inc. has a 52 week low of $13.9 and a 52 week high of $45.7. The company’s market cap is $821 million.
Global Blood Therapeutics, Inc. (GBT) last announced its earnings results on Nov 2, 2017. The company reported -0.66 earnings per share (EPS) for the quarter, lower than the consensus estimate of -0.61 by $0.05. During the same quarter in the previous year, the company posted -0.58 earnings per share.
|earnings per share||-0.66||-0.55||-0.74||-0.58||-0.53||-0.90||-4.84||-3.53||-3.68|
Global Blood Therapeutics, Inc. has been the subject of a number of recent research reports. Analysts at Morgan Stanley Maintains shares of Global Blood Therapeutics, Inc. to an Overweight rating in a research note. They now have a $51.00 price target on the stock.
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018